Each warrant authorises the holder to purchase one share of the Company’s Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable.
The offering was expected to close on June 30, 2020, subject to customary closing conditions.
Kensington Capital Acquisition V, a blank check business run by Kensington Capital’s founder and focused on industrials, filed with the SEC on Monday to raise up to $260 million.
The business, situated in Westbury, New York, hopes to generate $260 million by selling 26 million units at $10 each. One share of common stock and one-fifth of a warrant, exercisable at $11.50, are included in each unit. Kensington Capital Acquisition V would have a market value of $325 million at the anticipated deal size.
Company Profile
Kensington Capital Acquisition V was founded in 2021 and plans to list on the NYSE under the symbol KCGI.U. The company filed confidentially on June 10, 2021. UBS Investment Bank is the sole bookrunner on the deal. Kensington Capital Acquisition Corp. II operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
(Source: NASDAQ.com)
General Advice Warning
Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.
One common share and three-quarters of a common share purchase warrant are included in each Unit. Each Warrant authorises the holder to purchase one common share at a price of US$2.10 per common share for a period of 60 months following the closure of the Offering, subject to adjustment in certain conditions.
The Offering is scheduled to close on or around July 20, 2021, with the common shares underlying the Units and Warrants proposed for listing on the TSX and Nasdaq.
The Corporation plans to use the net proceeds of the Offering to continue clinical development of maveropepimut-S (DPX-Survivac) in DLBCL, breast cancer, ovarian cancer, bladder cancer, and microsatellite instability high (MSI-H), as well as to begin clinical development of a new product, DPX-SurMAGE, in bladder cancer, continuing to develop its patented drug delivery technology (DPX), as well as for other corporate reasons.
Company Profile
Albireo is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008.
(Source: RTT News)
General Advice Warning
Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.
The RBNZ said on 14/09 that it will abruptly cease its quantitative easing programme, prompting many economists to push back their forecasted NZ rate hike to August. The next gathering of the bank is set for August 18.
The Australian currency plummeted against the New Zealand dollar as a result of the announcement, with the Reserve Bank of Australia’s (RBA) own guidance indicating that rates will not be raised until 2024. Bank bill futures, on the other hand, suggest that the RBA will begin tightening in late 2022.
Australian dollar has been sliding in recent weeks
Following the June labour force report, which showed the unemployment rate fell to a decade-low 4.9 percent, the Australian dollar continued its downward trend on Thursday, falling 0.3 percent to US74.61. The Australian dollar has been sliding in recent weeks, falling over 3.5 percent in just the previous month.
Despite exceeding economists’ estimates, the robust jobs data failed to halt the downward trend. The labour survey came before Sydney’s draconian limitations and the imposition of a fifth lockdown for Victorians to control a new outbreak, so most investors ignored the news.
Experts Comments
“As the leader of the hiking bloc, money should just pile into the Kiwi,” said Westpac senior currency strategist Sean Callow. “The Australian will not gain much with the Kiwi, and we expect the cross rate to break substantially lower.”
“The market is now more worried about the consequences of the NSW lockdown on future months’ numbers,” said Ray Attrill, head of FX strategy at NAB. “GDP might be negative in the third quarter, which would support the RBA’s assertion that it is playing the long game.”
Source: afr
General Advice Warning
Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.